PLSH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PLSH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Panacea Life Sciences Holdings's revenue for the three months ended in Sep. 2024 was $0.95 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $4.14 Mil. Panacea Life Sciences Holdings's Revenue per Share for the three months ended in Sep. 2024 was $0.05. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.23.
Warning Sign:
Panacea Life Sciences Holdings Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Panacea Life Sciences Holdings was 109.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was -29.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 4 years, Panacea Life Sciences Holdings's highest 3-Year average Revenue per Share Growth Rate was -29.70% per year. The lowest was -29.70% per year. And the median was -29.70% per year.
The historical data trend for Panacea Life Sciences Holdings's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Life Sciences Holdings Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Revenue | 9.02 | 2.06 | 1.63 | 2.39 |
Panacea Life Sciences Holdings Quarterly Data | ||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Revenue | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
0.35 | 0.96 | 1.06 | 1.17 | 0.95 |
For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's Revenue distribution charts can be found below:
* The bar in red indicates where Panacea Life Sciences Holdings's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Life Sciences Holdings (OTCPK:PLSH) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of Panacea Life Sciences Holdings's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Leslie Buttorff | director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER | 16194 W 45TH DRIVE, GOLDEN CO 80403 |
Janice Nerger | director | 5910 S UNIVERSITY BLVD., C18-193, GREENWOOD VILLAGE CO 80121 |
Nathan Joel Berman | officer: CONTROLLER & PRIN ACTNG OFCR | 16194 W 45TH DRIVE, GOLDEN CO 80403 |
22nd Century Group, Inc. | 10 percent owner | 8560 MAIN STREET, SUITE 4, WILLIAMSVILLE NY 14221 |
Harvey J Kesner | 10 percent owner | 65 E. 55TH STREET, NEW YORK NY 10022 |
Lawrence Wert | director | 170 NUTTALL RD, RIVERSIDE IL 60546 |
Chesne Derek Du | officer: Chief Growth Officer | 80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483 |
Alvaro Daniel Alberttis | director | 80 NE 4TH AVENUE, SUITE 28, DELRAY BEACH FL 33483 |
Vladislav Yampolsky | director, 10 percent owner | 332 PLAZA REAL, BOCA RATON FL 33432 |
Steven A Schwartz | director | 332 PLAZA REAL, BOCA RATON FL 33432 |
Andrew L. Johnson | officer: Chief Strategy Officer | 80 NE 4TH AVE. SUITE 28, DELRAY BEACH FL 33483 |
Emiliano Angel Aloi | officer: President | 510 SUNSHINE DRIVE, DELRAY BEACH FL 33444 |
Jonathan Gilbert | director, officer: Executive Chairman | 36 SYCAMORE LANE, ROSALYN HEIGHTS NY 11577 |
John C Price | director | 4721 IRONTON STREET, BUILDING A, DENVER CO 80239 |
Kevin James Esval | director | NEURO HITECH INC, ONE PENN PLAZA STE 1503, NEW YORK NY 10019 |
From GuruFocus
By Marketwired • 07-20-2023
By Marketwired • 07-07-2023
By sperokesalga sperokesalga • 04-19-2023
By Marketwired • 05-16-2024
By Marketwired • 10-05-2023
By Marketwired • 10-02-2023
By Value_Insider Value_Insider • 10-26-2022
By Marketwired • 07-10-2023
By Marketwired • 08-08-2023
By Stock market mentor Stock market mentor • 01-23-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.